Real Assets

Real Assets

We build future energy systems and resilient infrastructure, backing emerging opportunities in technology, land and water.

Latest news

News

Natural Capital Horizons: Aligning capital, communities and policy

Latest news

News

Natural Capital Horizons: Aligning capital, communities and policy

Featured insight

Insights

Infrastructure for Energy Resilience: An investable system of assets and services

Skip to main content
Theme

WHEB investment theme: Health

Demand for better healthcare affects both developed and emerging economies. Growing demand is matched by growing pressure on health care budgets. Therefore, an area we prioritise is companies delivering healthcare at reduced cost including healthcare IT, diagnostics, and homecare, delivering both cost controls and technological advance.

Health

WHEB portfolio companies

Agilent Technologies

Agilent Technologies is a specialist in the development and manufacture of bio-analytics for the life sciences and chemical analysis industries. The company’s mission is to advance quality of life. Within healthcare, its analytical instruments are used in the development and testing of healthcare products. Agilent also has a chemical analysis business which makes equipment for monitoring levels of pollutants in the ambient environment and for measuring contaminants in food and the human body.

Visit website
AstraZeneca

AstraZeneca is a high-quality pharma company with a strong portfolio of commercial products that lead to better overall health outcomes for patients, who are often suffering from life-threatening or debilitating illness. The company's products treat a broad range of issues and target areas of high unmet need, particularly in the oncology and rare disease portfolios.



Visit website
Danaher

Danaher is a diversified business that designs, manufactures and sells laboratory equipment, consumables and services to clinical and medical laboratories including microscopes, analytical software and imaging and molecular devices. These tools are used in the development of new drugs and for diagnosing critically ill patients.



Visit website
Genmab

Genmab is a drug therapy company focused on differentiated antibody products in oncology. The company has developed industry-leading antibody discovery technologies which have led to a strong pipeline of potential best-in-class and first-in-class therapies. Through partnerships Genmab has successfully developed several products, including treatments for multiple myeloma, cervical cancer, multiple sclerosis and thyroid eye disease.


Visit website
Globus Medical

Globus Medical is a best-in-class spinal medical technology company headquartered in Pennsylvania, US. It has a large portfolio of solutions to promote healing in patients with musculoskeletal disorders. A newer, fast growing segment called “Enabling Technologies” centres around ExcelsiusGPS, the world’s first robotic navigation platform which supports surgeons in spinal operations. Globus Medical merged with its direct competitor NuVasive in September 2023. The company was founded in 2003.

Visit website
ICON

ICON is a clinical research organisation (CRO) which provides outsourced development services on a global basis to the pharmaceutical, biotechnology and medical device industries. The company’s mission is to accelerate the development of drugs and devices that save lives and improve the quality of life. ICON specialises in the strategic development, management and analysis of programmes to support all stages of the of the clinical development process.

Visit website
Lonza

Lonza is a Swiss chemicals contract development and manufacturing company (CDMO) operating across small molecules, biologicals, cell and gene, capsules, and health ingredients. CDMOs enable the use of state-of-the-art technology and equipment, bring scale, expertise and excellence to pharmaceutical manufacturing. CDMOs enable customers to deliver new, innovative medicines that help treat a wide range of diseases and accelerate the process to achieve commercial scale production. This results in lower cost and more effective medicines.

Visit website
Novo Nordisk

Novo Nordisk is a global healthcare company focused on the discovery, development, manufacturing and marketing of pharmaceutical products for the treatment of diabetes, obesity and haemophilia. Within the company’s diabetes and obesity segment it concentrates on insulin, GLP-1 and other protein-related products as well as delivery systems and needles and oral anti-diabetic drugs. Within the biopharmaceuticals segment, it covers haemophilia care, growth hormone therapy and hormone replacement therapy.

Visit website
Siemens Healthineers

Siemens Healthineers is a global medical technology company which was spun out of Siemens AG in 2017. Through four business segments, it specialises in the provision of diagnostic imaging, diagnostics, radiation oncology equipment and equipment for minimally invasive surgeries (MIS). All four segments help contribute towards either an improved quality of life and/or the life expectancy of patients.



Visit website
Thermo Fisher Scientific

Thermo Fisher Scientific is one of the largest suppliers of analytical instrument, equipment, consumables and software for healthcare and environmental research, analysis, discovery and diagnostics. The company offers a very wide range of products and services including the equipment needed to analyse samples as well as the variety of containers and other consumables needed to handle them. 



Visit website
Slide-Logo
Slide-Logo
Slide-Logo
Slide-Logo
Slide-Logo
Slide-Logo
Slide-Logo
Slide-Logo
Slide-Logo
Slide-Logo
white-background Slide-Image Slide-Image Slide-Image Slide-Image Slide-Image Slide-Image Slide-Image Slide-Image Slide-Image Slide-Image RippleV1-R1 RippleV1-R2 RippleV1-R3
UN Sustainable Development Goals (SDGs)

Links to SDG 3 Good Health and Well-being

Ensure healthy lives and promote well-being for all at all ages

About UN SDGs

Sustainable Development Goals

The UN Sustainable Development Goals (UN SDGs) were agreed by the world’s governments with the help and support of the United Nations in 2015.

The 17 goals set out aspirational and demanding targets for the world to achieve by 2030. This sends a powerful message to the investment community as to what the world’s governments consider as development priorities.

The SDGs are not used as an analysis framework within our investment process as our strategy predates them. However, we recognise that the SDGs are a useful framework for reporting. WHEB's strategy addresses seven of the SDGs directly and the remaining 10 indirectly and our quarterly reports detail portfolio alignment with the SDGs. 

News & Insights

You have viewed 0 of 0

Important Information

Foresight Group LLP does not offer legal, tax, financial or investment advice and the information on this website should not be construed as such. We recommend investors seek advice from a regulated financial adviser. The opportunity described in this document may not be suitable for all investors. Any such investment decision should be made only on the basis of the Fund scheme documents and appropriate professional advice.

Foresight Group LLP acts as investment manager and is authorised and regulated by the Financial Conduct Authority with Firm Reference Number 198020 and has its registered office at The Shard, 32 London Bridge Street, London SE1 9SG.

OEICs

An investment in FP Sustainable Future Themes Fund, FP Foresight Global Real Infrastructure Fund, FP Sustainable Real Estate Securities Fund, FP UK Infrastructure Income Fund or FP WHEB Sustainability Impact Fund and FP Foresight Diversified Real Assets Fund (together the “Funds”) should be considered a long-term investment that may be higher risk. Portfolio holdings are subject to change without notice.

The Authorised Corporate Directors FundRock Partners Limited (registered office at Hamilton Centre, Rodney Way, Chelmsford, England, CM1 3BY) and Liontrust Investment Partners LLP (registered office 2 Savoy Court, London WC2R 0EZ), are authorised and regulated by the Financial Conduct Authority with Firm Reference Numbers 469278 and 518552 respectively. The Funds are incorporated in England and Wales.

ICAVs

An investment in the WHEB Sustainable Impact Fund and the WHEB Environmental Impact Fund (together the “Funds”) should be considered a longer-term investment that may be higher risk. Portfolio holdings are subject to change without notice.

The Manager of the Funds is FundRock Management Company S.A., authorised and regulated by the Luxembourg regulator to act as UCITS management company and has its registered office at Airport Center Building, 5, Heienhaff, L-1736 Senningerberg, Luxembourg.

We respect your privacy and are committed to protecting your personal data. If you would like to find out more about the measures, we take in processing your personal information, please refer to our privacy policy, which can be found at http://www.foresight.group/privacy-policy.